Get the Stockscreener App
5.36
6.46%
-0.37
After Hours:
5.32
-0.04
-0.75%
Unicycive Therapeutics Inc stock is traded at $5.36, with a volume of 2.09M.
It is down -6.46% in the last 24 hours and down -22.54% over the past month.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
See More
Previous Close:
$5.73
Open:
$5.81
24h Volume:
2.09M
Relative Volume:
1.67
Market Cap:
$146.83M
Revenue:
$675.00K
Net Income/Loss:
$-26.62M
P/E Ratio:
-3.4134
EPS:
-1.5703
Net Cash Flow:
$-31.34M
1W Performance:
-30.39%
1M Performance:
-22.54%
6M Performance:
-5.13%
1Y Performance:
+16.52%
1-Day Range:
$5.25
$5.93
1-Week Range:
$3.93
$5.93
52-Week Range:
$3.71
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
5.36 | 128.47M | 675.00K | -26.62M | -31.34M | -1.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies - Yahoo Finance
Form 144 Unicycive Therapeutics For: 1 July By Investing.com - Investing.com Canada
[144] Unicycive Therapeutics, Inc. SEC Filing - Stock Titan
UNCY Maintained by Benchmark -- Price Target Lowered to $13.00 - GuruFocus
UNCY Maintained by Noble Capital Markets -- Price Target Lowered to $50 - GuruFocus
UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for - GlobeNewswire
Benchmark cuts Unicycive Therapeutics price target on FDA setback - Investing.com UK
Why Is Unicycive Therapeutics Stock Falling Tuesday? - Sahm
Unicycive Therapeutics: Second CRL Exposes Execution Risk Behind OLC Story (NASDAQ:UNCY) - Seeking Alpha
Benchmark cuts Unicycive Therapeutics price target on FDA setback By Investing.com - Investing.com South Africa
Powerful - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
UNCYUnicycive Therapeutics Inc Volatility & Greeks - Finviz
Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA - mydailyrecord.com
Unicycive plummets following second CRL for OLC for hyperphosphatemia - MSN
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Unicycive shares plunge after FDA issues complete response letter for kidney disease drug (UNCY) - MSN
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - TradingView
UNCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Law firm probes Unicycive Therapeutics after FDA rejects drug application, stock falls - Pluang
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors - GlobeNewswire
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors - GlobeNewswire Inc.
Unicycive receives FDA rejection for kidney disease drug - Investing.com UK
$Unicycive Therapeutics (UNCY.US)$ - Moomoo
Why is Unicycive Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
Unicycive gets FDA CRL for OLC kidney drug application - grafa.com
UNCY Extends ATM Offering As Dilution Fears Hit The Chart - StocksToTrade
US FDA declines to approve Unicycive's kidney disease drug - Reuters
US Stocks Mixed; Home Prices Increase 1.1% In April - Benzinga
Unicycive slides as FDA delay, dilution weigh premarket - TechStock²
FDA rejects drug again for same manufacturing issue, chopping stock in half - The Business Journals
UNCY Stock Slides As $150M Shelf Fuels Dilution Fears - timothysykes.com
Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY) - Yahoo Finance
Unicycive Therapeutics stock tumbles on FDA rejection letter - Investing.com
US FDA declines to approve Unicycive's drug for dialysis patients - marketscreener.com
Unicycive Therapeutics stock tumbles on FDA rejection letter By Investing.com - Investing.com Australia
Unicycive’s kidney drug hits FDA setback as label talks continue - Stock Titan
$Unicycive Therapeutics (UNCY.US)$ It is Good News. - Moomoo
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell 2000 Index - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell 2500 Growth Benchmark - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell Microcap Value Benchmark Index - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell 2000 Value Benchmark - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Unicycive Therapeutics stock reiterated at Buy by H.C. Wainwright - Investing.com Canada
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell 2000 Growth Benchmark - marketscreener.com
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell 3000E Growth Benchmark - marketscreener.com
Unicycive Therapeutics' Framework For Speedier Clinical Trials - Clinical Leader
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to Russell Microcap Index - marketscreener.com
Kaplan Fox Reminds Investors of Unicycive Therapeutics, Inc. (UNCY) to a Class Action Deadline on October 14, 2025 - The National Law Review
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, I - The National Law Review
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):